AUROPHARMA

Key Facts & Recent Developments

Recent Developments Building a strong pipeline in the U.S. with hundreds of ANDA approvals. Acquired U.S.-based Lannett to strengthen its American manufacturing footprint. In talks to acquire Zentiva in Europe, which could significantly expand its global reach. Latest quarterly results showed steady revenue growth but weaker profits due to rising costs and pricing pressures in the U.S. generics market. Financial Snapshot Current share price is around ₹1,100–1,120. 52-week high ~₹1,590; 52-week low ~₹1,010. Valuation stands around 19x earnings. ROE is about 10–12%, showing moderate profitability. Strengths Diversified global presence in both developed and emerging markets. Strong product pipeline with growing focus on biosimilars and complex generics. Acquisitions like Lannett and potential Zentiva buyout strengthen scale and market access. Stable revenue base with consistent expansion across segments. Risks U.S. pricing pressure in generics continues to squeeze margins. Higher operating costs and compliance expenses weigh on profitability. Stock is well below its 52-week high, showing investor caution. Regulatory risks remain a concern in all key markets. Market Outlook If overall market sentiment turns negative: Stock may test the support zone near ₹1,000–1,050. Any delay in acquisitions or regulatory approvals could amplify downside. Valuation multiples may contract further if earnings growth weakens. On the positive side, strong pipeline and global scale provide long-term growth potential.